UBS Group’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

UBS Group’s Portfolio ONCE Stock Details ONCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-700	Closed	-$72K	–	8493
2019 Q2	$72K	Sell	700 -800	-53%	-$86.3K	﹤0.01%	5624
2019 Q1	$171K	Buy	+1,500	New	+$110K	﹤0.01%	4714
2016 Q2	–	Sell	-155,000	Closed	-$4.57M	–	8118
2016 Q1	$4.57M	Buy	+155,000	New	+$4.89M	﹤0.01%	1944

UBS Group's ONCE Position: Q4 2019 in Review

UBS Group sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 130,654 shares — an estimated $12.7M sold.

UBS Group first reported a position in ONCE in Q1 2015 and held it in 19 quarters. The position peaked at $12.7M in Q3 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.

UBS Group reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
UBS Group sold 130,654 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $12.7M.
UBS Group first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 19 quarters.
UBS Group's Spark Therapeutics, Inc. Common Stock position peaked at $12.7M in Q3 2019.
0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.

Based on UBS Group's 13F filing for Q4 2019, filed 14 Feb 2020.